While the Sorafenib drug is not a big opportunity for Natco, approval from Kothur plant is a big positive, says Praful Bohra of Religare Capital Markets. Money Control, 3 weeks ago
Mumbai, Jun 12 () Indian pharmaceutical market grew 7.7 per cent in May compared with 3.5 per cent in April, but the ban on fixed-dose combination (FDC) drugs remains an overhang, says a report. According to data from the AIOCD-AWACS, the market ...Times of India, 1 week ago Pharma sector grows 7.7 per cent in May; FDC ban weighs Pharmaceutical Tech.com, 1 week ago Pharma Sector Grows 7.7% In May, Drug Ban Weighs: Report NDTV, 1 week ago Pharma sector grows 7.7% in May, FDC ban weighs Financial Express, 1 week ago
Related to : Aurobindo Pharma Ltd Aurobindo Pharma Ltd BSE 02 Jun 16 | 12:00 AM 789.50 0.25 (0.03%) NSE 02 Jun 16 | 12:00 AM 788.90 0.05 (0.01%) While pharmaceutical bigwigs such as Sun and Lupin faltered on the bourses after ...Smart Investor, 3 weeks ago Sun Pharma Shares Sink Nearly 7%, Inch Closer To 52-Week Low NDTV Profit, 3 weeks ago 'Glenmark to profit from drug price hike, +ve on Sun Pharma' Money Control, 1 month ago
Lupin's Goa plant is under US drug regulator's scanner Lupin shares sank over 8 per cent on Friday, even though analysts described the drugmaker's Q4 results as positive. Lupin, India's third-largest drugmaker, reported a higher than expected ...NDTV Profit, 1 month ago Goa plant woes a key overhang on Lupin: Experts Moneycontrol.com, 1 month ago
Dr Reddy's Pathlabs reported a sharp decline in its net profit of FY16 at Rs 74.6 crore over Rs 518.9 crore a year ago, due to one-time write-offs of Rs 430.9 crore from its Venezuelan business. The company has mentioned in its earnings report that ...Moneycontrol.com, 1 month ago
on your WebpageAdd Widget >Get your members hooked!